Afficher la notice abrégée

dc.contributor.authorCarrasco Peña, Francisco
dc.contributor.authorRodríguez Barranco, Miguel
dc.contributor.authorPetrova, Dafina 
dc.contributor.authorMarcos Gragera, Rafael
dc.contributor.authorSánchez Pérez, María José 
dc.date.accessioned2020-11-12T11:43:15Z
dc.date.available2020-11-12T11:43:15Z
dc.date.issued2020
dc.identifier.citationCarrasco-Peña, Francisco; Bayo-Lozano, Eloisa; Rodríguez-Barranco, Miguel; Petrova, Dafina; Marcos-Gragera, Rafael; Carmona-Garcia, Maria C.; Borras, Josep M.; Sánchez, Maria-José. 2020. "Adherence to Clinical Practice Guidelines and Colorectal Cancer Survival: A Retrospective High-Resolution Population-Based Study in Spain." Int. J. Environ. Res. Public Health 17, no. 18: 6697. [DOI: 10.3390/ijerph17186697]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/64225
dc.description.abstractColorectal cancer (CRC) is the third most common cancer worldwide. Population-based, high-resolution studies are essential for the continuous evaluation and updating of diagnosis and treatment standards. This study aimed to assess adherence to clinical practice guidelines and investigate its relationship with survival. We conducted a retrospective high-resolution population-based study of 1050 incident CRC cases from the cancer registries of Granada and Girona, with a 5-year follow-up. We recorded clinical, diagnostic, and treatment-related information and assessed adherence to nine quality indicators of the relevant CRC guidelines. Overall adherence (on at least 75% of the indicators) significantly reduced the excess risk of death (RER) = 0.35 [95% confidence interval (CI) 0.28–0.45]. Analysis of the separate indicators showed that patients for whom complementary imaging tests were requested had better survival, RER = 0.58 [95% CI 0.46–0.73], as did patients with stage III colon cancer who underwent adjuvant chemotherapy, RER = 0.33, [95% CI 0.16–0.70]. Adherence to clinical practice guidelines can reduce the excess risk of dying from CRC by 65% [95% CI 55–72%]. Ordering complementary imagining tests that improve staging and treatment choice for all CRC patients and adjuvant chemotherapy for stage III colon cancer patients could be especially important. In contrast, controlled delays in starting some treatments appear not to decrease survival.es_ES
dc.description.sponsorshipERANET within the framework of the call on "Translational research on tertiary prevention in cancer patients" (TRANSCAN)es_ES
dc.description.sponsorshipInstituto de Salud Carlos III AC14/00036es_ES
dc.description.sponsorshipAndalusian Department of Health, Research, Development, and Innovation PI-0152/2017es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectColorectal canceres_ES
dc.subjectAdherencees_ES
dc.subjectClinical practice guidelineses_ES
dc.subjectPopulation-based studyes_ES
dc.subjectHigh-resolution studyes_ES
dc.subjectCancer survivales_ES
dc.titleAdherence to Clinical Practice Guidelines and Colorectal Cancer Survival: A Retrospective High-Resolution Population-Based Study in Spaines_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3390/ijerph17186697


Fichier(s) constituant ce document

[PDF]

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

Atribución 3.0 España
Excepté là où spécifié autrement, la license de ce document est décrite en tant que Atribución 3.0 España